CSF3 and Barth syndrome: Indeed, when we stratified our Seahorse data, we observed that changes in mitochondrial activity were exclusively present in BTHS patients receiving G-CSF treatment, suggesting that these changes are more likely attributed to the treatment rather than intrinsic mitochondrial alternations caused by tafazzin dysfunction.